Evidence map›Paper›PMID 40056974›Full record

ArticleThe American journal of pathology2025

Toll-Interacting Protein Down-Regulation by Cigarette Smoke Exposure Impairs Human Lung Defense against Influenza A Virus Infection.

Hina Agraval, Junfeng Gao, Niccolette Schaunaman, Huang Hua, R William Vandivier, Mari Numata, Brian J Day, Hong Wei Chu

Abstract read
In one paragraph

Article in The American journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hina AgravalDepartment of Medicine, National Jewish Health, Denver, Colorado.
Junfeng GaoDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, Colorado.
Niccolette SchaunamanDepartment of Medicine, National Jewish Health, Denver, Colorado.
Huang HuaDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, Colorado.
R William VandivierDivision of Pulmonary Science and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Mari NumataDepartment of Medicine, National Jewish Health, Denver, Colorado.
Brian J DayDepartment of Medicine, National Jewish Health, Denver, Colorado.
Hong Wei ChuDepartment of Medicine, National Jewish Health, Denver, Colorado. Electronic address: chuhw@njhealth.org.

Funding

Tollip inhibits IL-33 signaling during airway influenza virus infectionU19AI125357 · NIAID · UNIVERSITY OF ARIZONA · PI CARR, TARA F · 2016 to 2025
$14.7M
Immunosuppressive injurious effects of e-cigarettes on human lung parenchymaR01HL144396 · NHLBI · NATIONAL JEWISH HEALTH · PI CHU, HONG W, PETRACHE, IRINA · 2018 to 2021
$1.9M
NHLBI NIH HHS R01 HL144396NIAID NIH HHS U19 AI125357
6 · The paper itself

Abstract

Cigarette smoking is a primary cause of chronic obstructive pulmonary disease (COPD). Smokers have a higher risk of influenza-related mortality, but the underlying mechanisms remain unclear. Toll-interacting protein (TOLLIP), an immune regulator, inhibits influenza A virus (IAV) infection, but its regulation in COPD has not been well understood. This study was designed to determine whether cigarette smoke (CS) exposure down-regulated TOLLIP expression via epigenetic mechanisms, including histone methylation. TOLLIP and histone-methylating enzymes enhancer of zeste homolog 1/2 (EZH1/2) were measured in healthy and COPD human lungs, human airway epithelial cells cultured under submerged and air-liquid interface conditions, and precision-cut lung slices (PCLSs) exposed to CS with or without IAV infection. EZH1/2 siRNA and inhibitors were used to investigate their effects on TOLLIP expression. In patients with COPD, TOLLIP levels decreased, whereas EZH1 and EZH2 expression increased. Repeated CS exposure decreased TOLLIP and increased EZH1, EZH2, trimethylation of histone H3 at lysine 27 (H3K27me3), and IAV levels in human airway epithelial cells and PCLSs. EZH1/2 siRNA or their pharmacologic inhibitor valemetostat tosylate, in part, restored TOLLIP and reduced IAV levels in CS-exposed airway epithelial cells and PCLSs. These findings suggest that repeated CS exposure during viral infection reduced TOLLIP levels and increased viral load in part through EZH1/EZH2-H3K27me3-mediated epigenetic mechanisms. Targeting EZH1 and EZH2 may serve as one of the potential therapeutic strategies to restore TOLLIP expression and host defense against viral infections in patients with COPD.

Indexed as

Cigarette SmokingInfluenza A virusInfluenza, HumanIntracellular Signaling Peptides and ProteinsLungPulmonary Disease, Chronic ObstructiveDown-RegulationEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticEpithelial CellsFemaleHumansMaleMiddle AgedEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanIntracellular Signaling Peptides and ProteinsTOLLIP protein, human

Identifiers

PMID40056974
PMCPMC12163395

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.